FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Inhibikase Therapeutics Inc (IKT)
-
-
-
-
-
-
-
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
-
-
-
-
-
-
-
Inhibikase Therapeutics (IKT) Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
-
-
-
-
-
-
-
Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
-
-
-
-
-
-
-
Inhibikase Therapeutics (IKT) Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
-
-
-
-
-
-
-
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
-
-
-
-
-
-
-
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

